Imperial College London
Portrait Picture

Professor Mona El-Bahrawy

Faculty of Medicine, Department of Metabolism, Digestion and Reproduction

Professor of Practice (Histopathology)
 
 
 
//

Contact

 

m.elbahrawy

 
 
//

Location

 

Department of HistopathologyHammersmith HospitalHammersmith Campus

//

Summary

 

Publications

Citation

BibTex format

@article{Montinaro:2022:10.1038/s41418-021-00869-x,
author = {Montinaro, A and Areso, Zubiaur I and Saggau, J and Kretz, A-L and Ferreira, RMM and Hassan, O and Kitzig, E and Mueller, I and El-Bahrawy, MA and von, Karstedt S and Kulms, D and Liccardi, G and Lemke, J and Walczak, H},
doi = {10.1038/s41418-021-00869-x},
journal = {Cell Death and Differentiation},
pages = {492--503},
title = {Potent pro-apoptotic combination therapy is highly effective in a broad range of cancers},
url = {http://dx.doi.org/10.1038/s41418-021-00869-x},
volume = {29},
year = {2022}
}
Download

RIS format (EndNote, RefMan)

TY  - JOUR
AB  - Primary or acquired therapy resistance is a major obstacle to the effective treatment of cancer. Resistance to apoptosis has long been thought to contribute to therapy resistance. We show here that recombinant TRAIL and CDK9 inhibition cooperate in killing cells derived from a broad range of cancers, importantly without inducing detectable adverse events. Remarkably, the combination of TRAIL with CDK9 inhibition was also highly effective on cancers resistant to both, standard-of-care chemotherapy and various targeted therapeutic approaches. Dynamic BH3 profiling revealed that, mechanistically, combining TRAIL with CDK9 inhibition induced a drastic increase in the mitochondrial priming of cancer cells. Intriguingly, this increase occurred irrespective of whether the cancer cells were sensitive or resistant to chemo- or targeted therapy. We conclude that this pro-apoptotic combination therapy has the potential to serve as a highly effective new treatment option for a variety of different cancers. Notably, this includes cancers that are resistant to currently available treatment modalities.
AU  - Montinaro,A
AU  - Areso,Zubiaur I
AU  - Saggau,J
AU  - Kretz,A-L
AU  - Ferreira,RMM
AU  - Hassan,O
AU  - Kitzig,E
AU  - Mueller,I
AU  - El-Bahrawy,MA
AU  - von,Karstedt S
AU  - Kulms,D
AU  - Liccardi,G
AU  - Lemke,J
AU  - Walczak,H
DO  - 10.1038/s41418-021-00869-x
EP  - 503
PY  - 2022///
SN  - 1350-9047
SP  - 492
TI  - Potent pro-apoptotic combination therapy is highly effective in a broad range of cancers
T2  - Cell Death and Differentiation
UR  - http://dx.doi.org/10.1038/s41418-021-00869-x
UR  - http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000696754600001&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=1ba7043ffcc86c417c072aa74d649202
UR  - http://hdl.handle.net/10044/1/92152
VL  - 29
ER  -
Download